医薬品・医療機器に関する主要政策

食品医薬品安全処

目次

Ⅰ. 医薬品に関する政策

国家必須医薬品の安定供給に向けた基盤の整備

- 定義

  ✓ 「国家必須医薬品」とは、疾病管理、放射能対策などの保健医療上必要不可欠なものの市場の機能だけでは安定供給が難しい医薬品で、保健福祉部（省に該当）長官と食品医薬品安全処長が関係中央行政機関の議長と協議して指定するものをいう。

- 目的

  ✓ 患者の治療に必要不可欠だが、市場の機能だけでは適正な供給が行われにくい国家必須医薬品について、予測をもとに事前に供給する政府による安全供給システムを整備

Ⅰ. 医薬品に関する政策

国家必須医薬品の安定供給に向けた基盤の整備

- 根拠法令

✓ 薬事法第83条の3（国家必須医薬品の安定供給基盤の整備、2016.12.2改正）

❖ 主な業務

1. 国家必須医薬品安定供給総合対策の策定・推進
2. 国家必須医薬品の安定供給基盤の整備と研究開発および安全な使用に向けた支援
3. 必要に応じた行政的・財政的・技術的な支援
4. 食品医薬品安全処に国家必須医薬品安定供給協議会を設置
5. 国家必須医薬品安定供給協議会の構成・運営等に必要な事項は大統領令で定める

Ⅰ. 医薬品に関する政策

国家必須医薬品の安定供給に向けた基盤の整備

- 推進体制

- 9つの政府部処(省庁)と5つの専門団体が安定供給協議会を中心として国家必須医薬品の供給情報を迅速に共有し、供給不安定に共同で対応

Ⅰ．医薬品に関する政策

国家必須医薬品の安定供給に向けた基盤の整備

- 国家必須医薬品の管理

✓ 国家備蓄用医薬品

– 国の緊急事態や政策目的の達成に必要不可欠で、備蓄・供給する必要がある医薬品。備蓄適正量を常に維持できるように管理

✓ 供給中断時の支援医薬品

– 医療上必要不可欠だが、市場の機能だけでは安定供給が困難な医薬品。供給が中断した場合は委託生産、特例輸入などにより正常化を支援

Ⅰ. 医薬品に関する政策

医薬品品目更新制度

- 目的
  - ✓ 医薬品の安全性と有効性を継続的に確保するために品目許可を取得したか品目申告をした医薬品について、5年ごとに許可または申告を更新

- 関連法令
  - ✓「薬事法」第31条の5（医薬品品目許可等の更新）
    - – 医薬品の品目許可および品目申告の有効期間は5年とする。
    - – 品目許可を受けた者は、有効期間満了後も引き続き当該医薬品を販売するためには、その有効期間が満了する前に食品医薬品安全処長から品目許可の更新を受けるか、品目申告を更新しなければならない。

※ 上記の期間が過ぎた場合、品目許可（申告）は失効する

Ⅰ. 医薬品に関する政策

医薬品品目更新制度

- 更新対象
  - ✓ すべての医薬品
    - ただし、原料医薬品、輸出用医薬品（許可条件）を除く

- 有効期間
  - ✓ （**新規**）医薬品品目許可（申告）に対し5年の有効期間を付与（法第31条の5第1項）
  - ✓ （**既許可**）**分類番号ごとに有効期間（2018～2023年内）を指定**
    「医薬品品目許可および品目申告の有効期間の指定に関する規定」[別表1]



Ⅰ．医薬品に関する政策

医薬品品目更新制度

- 提出資料

  - ✓ 有効期間中に収集された安全管理に関する資料および措置計画
  - ✓ 海外での使用状況および安全性関連措置に関する資料
  - ✓ 有効期間中に収集された品質管理に関する資料
  - ✓ 表示記載に関する事項
  - ✓ 製造・輸入実績に関する資料
  - ✓ 製造販売・輸入品目許可証または品目申告証の写し

II. 医療機器に関する政策

医療機器の許可･新医療技術評価の統合運営

- 目的
  - ✓ 医療機器の許可(食品医薬品安全処)と新医療技術評価(保健福祉部)の迅速かつ効率的な運営を目指し、「医療機器の許可･新医療技術評価等の統合運営」制度を導入

- 根拠法令
  - ✓「医療機器法施行規則」を改正(国務総理令)(‘16.7)
  - ✓「新医療技術評価に関する規則」を改正(保健福祉部令)(‘16.7)
  - ✓「国民健康保険療養給付の基準に関する規則」を改正(保健福祉部令)(‘16.7)
  - ✓「医療機器の許可･新医療技術評価等の統合運営に関する規定」を制定(‘16.7)

II. 医療機器に関する政策

医療機器の許可・新医療技術評価の統合運営

- 統合運営の対象

✓ 医療機器の使用目的が医療技術の使用目的と一致

- 使用目的、方法および対象が一致
- 医療機器の使用目的が医療技術の使用目的より包括的
- 医療機器と一緒に使用されるS/Wの機能が医療技術の使用目的と一致

✓ 治験資料または臨床的性能試験資料の提出が必要な医療機器

- すでに同資料を添付して許可を得た医療機器と構造、原理、性能、使用目的・使用方法などが本質的に同じである場合も対象に含まれる

II. 医療機器に関する政策

医療機器の許可･新医療技術評価の統合運営

- 主な内容

✓ 医療機器の許可(食品医薬品安全処)、療養(非)給付対象であるかの確認(健康保険審査評価院)、新医療技術評価(韓国保健医療研究院)の統合運営および食品医薬品安全処のシングルウィンドウ(single window)の整備

▶ 3つの機関の3つのサービス窓口を食品医薬品安全処に一本化(資料共有、意見交換などの調整)

改善前	改善後
医療機器の許可(80日)▶療養(非)給付対象であるかの確認(30～110日)▶新医療技術評価(280日) “順次実施”	医療機器の許可(80日)、療養(非)給付対象であるかの確認(30～110日)、新医療技術評価(280日) “同時実施、共同検討”
最大470日所要	80日～280日所要

II. 医療機器に関する政策

部処(省庁)合同で先端医療機器のライフサイクル全体にわたって製品化を支援

- 目的

  ✓ R&D、治験、許可など各分野の専門家からなるメンタリング専門人材プールを運営して製品化の成功率を高め、企業の早期の市場参入を支援

- 次世代医療機器100プロジェクト

  ✓ 有望医療機器を選定(毎年20品目、5年間で100品目)し、製品化の全プロセスにおいて体系的な技術支援を提供

  ※ 3Dプリンターで製作した人工関節、認知症の早期診断、医療機器など20の製品を選定・支援('16年)

II. 医療機器に関する政策

部処(省庁)合同で先端医療機器のライフサイクル全体にわたって製品化を支援

- 融合・複合医療機器活性化推進団
  - ✓ 政府部処(省庁)と関係機関が合同でR&Dや製品開発における問題などを解消

    ※ 食品医薬品安全処、未来創造科学部、産業資源部、保健福祉部、中小企業庁、産業協会、情報技術支援センター、尖端医療福祉団地など

- カスタマイズ型メンタリング専門家および専門組織の構成
  - ✓ (分野別の専門家) 支援環境に応じて必要な分野の専門家で構成

区 分	計	R&D	治験	許可	GMP
人数	478	138	192	102	46

  - ✓ (メンタリング専門組織) 分野別専門人材5人で構成

    「医療機器情報技術支援センター」にカスタマイズされたメンタリング運営専門組織を設置

2nd Japan – Korea Joint Symposium on Medical Products

Latest trend of pharmaceutical and medical device regulation in Japan

Mr. Yoshihiko Sano,

Deputy Director, Office of International Regulatory Affairs

Pharmaceutical Safety and Environmental Health Bureau

Ministry of Health, Labour and Welfare (MHLW)

11th May 2017

Contents

1. Organizational Updates of MHLW/PMDA
2. Regulatory measures to promote innovation
3. Regulatory Cooperation with International Society



1. Organizational Updates of MHLW/PMDA

Regulatory Authorities in JAPAN

MHLW – PSEH Bureau

Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health Labour and Welfare

- **Final Authorization of applications**
- **Publishing Guidelines**
- **Advisory committee**
- **Supervising PMDA Activities**

PMDA

Pharmaceuticals and Medical Devices Agency

- **Scientific Review for Drugs & Medical Devices**
- **GCP, GMP Inspection**
- **Consultation on Clinical Trials etc.**

Reform of Pharmaceutical Safety and Environmental Health Bureau




organization chart
Executive Director
Director of Center for Product Evaluation
Deputy Center Director (for Cellular and Tissue-based Products)
Deputy Center Director (for Medical Devices)
Chief Executive
Auditor
Audit Office
Senior Executive Director
Director of Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs
Executive Director
Deputy Executive Director
Associate Center Director
Associate Executive Director
Associate Center Director
Associate Center Director
Associate Center Director
Associate Executive Director
Associate Center Director
Chief Safety Officer
Associate Executive Director
Associate Executive Director
Associate Center Director
Chief Relief Officer
Chief Management Officer
Associate Center Director
Office of Regulatory Science
Office of Review Administration
Office of Review Management
Coordination Officer for Review of Breakthrough Products (Sakigake)
Coordination Officer for Pharmaceutical Affairs Consultation on R&D
Office of Standards and Guidelines Development
Offices of New Drug I-V
Office of Cellular and Tissue-based Products
Office of Vaccines and Blood Products
Office of Non-clinical and Clinical Compliance
Office of OTC/Quasi-drugs
Office of Generic Drugs
Offices of Medical Devices I-III
Office of In Vitro Diagnostics
Principal Senior Scientists
Senior Scientists
Advanced Review with Electronic Data Promotion Group
Office of Manufacturing/ Quality and Compliance
Office of Medical Informatics and Epidemiology
Offices of Safety I, II
Information Technology Promotion Group
Coordination Officer for Information Technology Promotion
Office of International Programs
International Coordination/Liaison Officers
Office of International Cooperation
International Senior Training Coordinator
Kansai Branch / Hokuriku Branch
Chief Actuary
Office of Relief Funds
Offices of General Affairs / Office of Financial Management / Director for Personnel Affairs and Human Resources Development
Office of Planning and Coordination
As of June 21, 2016

Cooperation between MHLW and PMDA



New Drug Marketing Approval Process



PAFSC : Pharmaceutical Affairs and Food Sanitation Council

PMDA Staff Size



High performance at review speed



http://www.cirsci.org/wp-content/uploads/2016/05/CIRS_RD_-Briefing_59_23052016.pdf

2. Regulatory measures to promote innovation

- 2nd Round of *Sakigake* Designation
- Conditional Early Approval System
- Projects for the use of Real World Data
- Optimal Clinical Use Guideline





SAKIGAKE Designation – 2nd Round



Designated in 1st round pilot (Oct. 2015)

6 Pharmaceuticals, 2 Medical Devices, 3 Regenerative Products

Designated in 2nd round pilot (Feb & April. 2017)

5 Pharmaceuticals, 3 Medical Devices, 1 In-Vitro Diagnostic, 3 Regenerative Products

2nd Round of SAKIGAKE Pharmaceuticals (21st Apr 2017)

Name of product	Planned indications	Name of applicant
Olipudase Alfa (Genetical Recombination)	Acid Sphingomyelinase Deficiency	Sanofi KK
aducanumab	Suppression of Alzheimer's disease progression	Biogen Japan Ltd.
DS-5141b	Duchenne muscular dystrophy (DMD)	Daiichi Sankyo Co., Ltd.
SPM-011※	- Recurrent malignant glioma - Unresectable locally recurrent head and neck cancer and locally advanced head and neck cancer (non-squamous cell carcinoma)	Stella Pharma Corporation
Nivolumab (Genetical Recombination)	Biliary tract cancer	Ono Pharmaceutical Co., Ltd.

2nd Round of *SAKIGAKE* Designated Products
- Regenerative Medical Products and *In-Vitro* Diagnostic -

(28th Feb 2017)

Name of product	Summary of product	Name of applicant
CLS2702C/D (Oral mucosa-derived esophageal cell sheet)	Shorter re-epithelialization period after extensive endoscopic submucosa dissection (ESD) in esophageal cancer.	**CellSeed** (Seeds: **Tokyo Women's Medical University Hospital**)
Dopamine neural precursor cell derived from non-autologous iPS cell (Therapeutic stem cell for Parkinson's disease)	Novel therapy by inducing dopamine discharge to mitigate neural symptoms of patients with Parkinson's disease.	**Sumitomo Dainippon Pharma Co., Ltd.** (Seeds: **Center for iPS Cell Research and Application, Kyoto University**)
Pluripotent progenitor cell derived form human (allogeneic) adult bone marrow (Stem cell suspension derived from adult marrow)	Novel therapy for improving functional impairment caused by acute brain infarction.	**Healios K.K.** in Japan **Athersys** (US company) outside of Japan
Cancer-related gene panel examination system (Diagnostic system for DNA sequencer)	Collective examination of cancer-related genes to aid decisions on cancer treatment strategies	**Sysmex Corporation** (Seeds: National Cancer Center)

2nd Round of *SAKIGAKE* Designated Products
- Medical Devices -

(28th Feb 2017)

Name of product	Summary of product	Name of applicant
Artificial tracheal (made of polypropylene mesh and collagen sponge)	Aiding reconstruction of tracheal while maintaining intratracheal structure after partial removal.	**Daiichi Medical** (Seeds: **Kyoto University**, etc.)
Boron neutron capture therapy (BNCT) system (Neutron irradiation system for BNCT)	Selective destruction of tumor cells marked by boron agents, without damaging normal cells.	**Stella Pharma Corporation Sumitomo Heavy Industries, Ltd.** (Seeds: **Kyoto University**, etc.)
UT-Heart (Software program to aid prediction of effectiveness of cardiac resynchronization therapy)	Higher accuracy of prediction of effectiveness of cardiac resynchronization therapy for patients with serious heart failure.	**Fujifilm Corporation UT-Heart Inc.** (A venture company by The University of Tokyo)

Conditional Early Approval System (for pharmaceuticals)

- Efficacy and safety will be ensured by using the rational and scientific post-marketing data (including the Real-World Data※). Regulations will be modified to confirm the approved content and expand indications.

※ **Real-world data includes MID-NET and registry data of Clinical Innovation Network.**

- Promote "Optimal use Guideline" based on regulatory science as well.
- Details of "Conditional Early Approval" will be finalized by summer of 2017.



Accelerated approval Scheme for Innovative Medical Devices (Draft)

"There are cases where innovative MDs created by medical venture enterprises are expected to have extremely effective and safe profile, however, these MDs target extremely few patients. In such cases, the development might be stagnated because of difficulties in collecting patients for clinical trial.

Considering such a situation and our mission to introduce innovative MDs to the public, **the government should construct the scheme which accelerate the approval of the innovative MDs by minimising the burden regarding clinical trials and enhancing the post-market surveillance**."

From the Report by Conference for promotion of Venture companies driving clinical innovations (July 2016)

Subjects to be solves

- The scope of the scheme
- The way of pre-market review with limited number of clinical cases, overseas data and literature
- Post-market safety monitoring system which enables accelerated approval …etc.

Expedited approval system under PMD Act

< Drawback of traditional PAL approval system >
Long-term data collection and evaluation in clinical trials, due to the characteristics of cellular/tissue-based products, **such as non-uniform quality** reflecting individual heterogeneity of autologous donor patients

[Traditional approval process]



[New scheme for regenerative medical products]



Post-marketing safety measures must be taken, including prior informed consent of risk to patients

On-going projects for the use of Real World Data

Clinical Innovation Network (CIN) is an infrastructure to support conducts of efficient clinical trials using patient's registered information.



MID-NET（Medical Information Database Network） is a project to establish the DB network for MIHARI Project to utilize electronic healthcare data for drug safety.



3. Regulatory Cooperation with International Society

- 7th International Meeting of World Pharmacopoeias
- ICH (International Council for Harmonization)
- PMDA Asia Training Center
- 12th Summit of Heads of Medicines Regulatory Agencies and ICMRA in Oct 2017 in Kyoto



Global Activities

Summit	ICH	IMDRF	PIC/S	HBD	ICDRA
APEC LSIF RHSC	OECD	PDG	IDGRP	ICMRA	

And so on

Abbreviation	Official Name
Summit	International Summit of Heads of Medicines Regulatory Agencies
ICH	International Conference on Harmonization
IMDRF	International Medical Device Regulators Forum
PIC/S	Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme
HBD	Harmonization By Doing
ICDRA	International Conference of Drug Regulatory Authorities
APEC LSIF RHSC	APEC Life Science Innovation Forum Regulatory Harmonization Steering Committee
OECD MAD	OECD Mutual Acceptance of Data
PDG	Pharmacopoeial Discussion Group
IGDRP	International Generic Drug Regulators Pilot
ICMRA	International Coalition of Medicines Regulatory Authorities

ICH and its Reform

About ICH *International Council for Harmonization

- International harmonization project of technical requirements involving the Regulators and research-based Industries
- Accomplished through the development and implementation of harmonized Guidelines

ICH Reform (Oct. 2015)

- MHLW/PMDA is one of the founding regulatory members
- **New membership application is now open for regulators and industries in global society**
- Guidelines development will be further activated

Recent Progress of ICH

- Participation of New Regulatory Members (in Nov. 2016)
  - ANVISA (Agência Nacional de Vigilância Sanitária, Brazil)
  - MFDS (Ministry of Food and Drug Safety, Korea)
- Progress in ICH Guideline Development
  - E17 (Multi-Regional Clinical Trials): Step 2 in 2016 and Step 4 envisaged in Nov. 2017
  - M10 (Bioanalytical Method Validation): One of the two Expert WGs established in 2016 with the rapporteur from MHLW/PMDA
- GCP Renovation (led by FDA)
  - Comprehensive review of clinical trial design and GCP related guidelines to incorporate the use of Real World Data in the regulation

MHLW/PMDA assigns the largest number of Rapporteurs for WGs

(EWG/IWGs active on Mar. 2017)

"Rapporteur" is the expert who leads the scientific discussion and Guideline development in each ICH Working Group.

Member	WG with its Rapporteur	
MHLW/PMDA	E2B, E11, E17, M2*, M8, M10, S3A	**7**
FDA	E18, S9, Q3C, Q3D, M2*, M7	6
EC/EMA	S5, E9, M2*, M9, Q11	5
JPMA		0
PhRMA	Q12, S1, S11, E14/S7B	4
EFPIA	M1	1
Health Canada		0
Swissmedic		0
Total		23

* "Co-Rapporteurs" are nominated for M2 WG.

Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (Est. April 2016)

- Plan, design and coordinate training for Asian regulatory authority staff
- Provide **training opportunities** including **on-site training**

⇨ Help raise the level of regulations in Asia as a whole.



ATC Completed Trainings: FY2016 (April 2016 – March 2017)

No.	Contents	Date	Location	Number of participants
1	Pharmaceuticals Review	July 25-29, 2016	Tokyo (PMDA)	13 participants from 7 economies
2	Pharmaceuticals Review	Sep. 26-29, 2016	Bangkok	13 participants from Thailand and Hong Kong
3	Medical Devices	Nov. 7-11, 2016	Tokyo (PMDA)	28 participants from 13 economies
4	Good Registration Management	Nov. 15-17, 2016	Taipei	28 participants from 10 economies
5	Good Manufacturing Practice	Dec. 5-9, 2016	Toyama City, Toyama Prefecture	19 participants from 12 economies
6	Multi-Regional Clinical Trial	Jan. 23-26, 2017	Tokyo (PMDA)	32 participants from 14 economies
7	Pharmacovigilance	Feb. 6-9, 2017	Tokyo (PMDA)	28 participants from 15 economies

In total 161 Regulators from 27 countries/regions participated.

ATC Planned Trainings: FY2017 (April 2017 – March 2018)

No.	Contents	Date	Location
1	Risk Management Plan (RMP)	May, 2017 (TBD)	Jakarta
2	Pharmaceuticals Review	June 26-30, 2017	Tokyo (PMDA)
3	Good Manufacturing Practice (GMP)	July, 2017 (TBD)	Hikari City, Yamaguchi Prefecture
4	Anti-infective Drugs	Oct., 2017 (TBD)	Vietnam (TBD)
5	Medical Devices	Nov., 2017 (TBD)	Tokyo (PMDA)
6	Good Registration Management (GRM)	Nov., 2017 (TBD)	Taipei
7	Pharmaceuticals Review	Dec., 2017 (TBD)	Bangkok
8	Multi-Regional Cinical Trial (MRCT)	Jan., 2018 (TBD)	Tokyo (PMDA)
9	Pharmacovigilance	Feb., 2018 (TBD)	Tokyo (PMDA)

Summit and ICMRA 2017 in Kyoto

Japan will host the 12th Summit of Heads of Medicines Regulatory Agencies, ICMRA (International Coalition of Medicines Regulatory Authorities) and "Summit Symposium" in Oct. 23-27 2017 in Kyoto.

Summit of the Heads of Medicines Regulatory Agencies: started in 2006; consists of the heads of 23 regulatory agencies; chaired by a host country; and discusses the future vision of regulation (Regenerative Medical Products, Novel Information Databases, AMR, SSFFC .etc).

ICMRA (International Coalition of Medicines Regulatory Authorities): started in 2012; consists of 22 regulatory agencies; chaired by MHRA (UK) at present; and discusses strategically important areas (Crisis Management, Pharmacovigilance, and Supply Chain Integrity .etc).

"Innovation" will be the key theme through the Summit and ICMRA 2017.

Symposium of the Summit of Heads of Medicines Regulatory Agencies

- Date: Oct. 27, 2017 (Fri) *Keep the date!*
- Venue: Kyoto International Conference Center (KICC) – Main Hall
- Hosts: MHLW, PMDA, Kyoto Prefecture, DIA Japan
- Supports: JPMA, JFMDA
- Contents:

1. "For innovative technology and its practical use"

   Speech by: Prof. **Shinya Yamanaka**, key Regulatory and Industry Representatives

2. "Actions and challenges by Regulatory Agencies *~From the results of 12th Summit and ICMRA~*"

   Speech and discussion by: **Core members of Summit and ICMRA**

All the players in good harmony

Thank you for your attention.

See you again in Kyoto!